

# ASX Release

---

## HC Berlin Pharma Update

**PERTH, AUSTRALIA – 4 May 2018:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, provides an update to the matter with HC Berlin Pharma.

Following the ASX announcement of 1 May 2018, the Receiver of HC Berlin Pharma has requested that we postpone the meeting until Wednesday 16 May.

SUDA will provide a further update following those discussions taking place.



**Further information:**

**STEPHEN CARTER**

**EXECUTIVE CHAIRMAN**

**SUDA Pharmaceuticals Ltd**

Tel: +61 8 6142 555

[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

**NOTES TO EDITORS:**

**About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)